Virtu Financial LLC Alaunos Therapeutics, Inc. Transaction History

Virtu Financial LLC

$1.43 Billion
Q2 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	BUY	$1.04 - $322.5 $77,575 - $24.1 Million	74,592 New	74,592 $128,000
Q1 2022 May 17, 2022	SELL	$0.62 - $1.17 $33,184 - $62,623	-53,524 Closed	0 $0
Q4 2021 Feb 17, 2022	SELL	$1.09 - $1.89 $6,543 - $11,345	-6,003 Reduced 10.08%	53,524 $58,000
Q3 2021 Nov 12, 2021	BUY	$1.44 - $2.73 $85,718 - $162,508	59,527 New	59,527 $108,000
Q2 2021 Sep 17, 2021	SELL	$2.63 - $3.67 $184,097 - $256,896	-69,999 Closed	0 $0
Q1 2021 May 19, 2021	BUY	$2.82 - $5.6 $197,397 - $391,994	69,999 New	69,999 $252,000
Q4 2020 Feb 24, 2021	SELL	$2.09 - $3.09 $31,500 - $46,572	-15,072 Closed	0 $0
Q3 2020 Dec 11, 2020	BUY	$2.39 - $3.43 $36,022 - $51,696	15,072 New	15,072 $38,000
Q4 2019 Feb 04, 2020	SELL	$3.95 - $5.35 $97,237 - $131,700	-24,617 Closed	0 $0
Q3 2019 Nov 20, 2019	SELL	$4.13 - $6.94 $138,933 - $233,461	-33,640 Reduced 57.74%	24,617 $105,000
Q2 2019 Aug 13, 2019	BUY	$3.98 - $6.2 $49,308 - $76,811	12,389 Added 27.01%	58,257 $340,000
Q1 2019 Apr 12, 2019	SELL	$2.0 - $4.4 $38,360 - $84,392	-19,180 Reduced 29.49%	45,868 $177,000
Q4 2018 Jan 16, 2019	BUY	$1.61 - $3.62 $104,727 - $235,473	65,048 New	65,048 $122,000
Q2 2018 Jul 30, 2018	SELL	$3.02 - $4.94 $39,658 - $64,872	-13,132 Closed	0 $0
Q2 2018 Jul 30, 2018	SELL	$3.02 - $4.94 $48,622 - $79,534	-16,100 Reduced 55.08%	13,132 $40,000
Q1 2018 May 14, 2018	SELL	$3.46 - $5.14 $240,144 - $356,746	-69,406 Reduced 70.36%	29,232 $115,000
Q4 2017 Feb 09, 2018	BUY	$4.0 - $6.54 $354,192 - $579,103	88,548 Added 877.58%	98,638 $408,000
Q3 2017 Nov 15, 2017	BUY	$4.99 - $6.57 $50,349 - $66,291	10,090	10,090 $0

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.

Account